2019

Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.

Urgent actions are needed now to prevent a collapse of diagnostic testing.

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Hospital pharmacists and regulators lead the way on shortages

EHA welcomes initiatives but calls for more focus on causes

Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.

EHA to the European Commission and HTA leaders: work with medical societies to involve experts and make joint assessments a success

The speakers of the HTA conference hosted by the European Commission.

GAPP Joint Action

Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.

Myeloproliferative neoplasms better understood through scientific meeting

The EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms held on October 12-14, 2017 in Budapest, Hungary received a 100% recommendation rating from attendees.